On this page
- TL;DR
- Onychomycosis VA rating criteria (DC 7813)
- How VA measures nail fungus: body area and exposed area
- Oral antifungals and the systemic-therapy route
- Diagnosing onychomycosis for a VA claim
- How to prove onychomycosis is service connected
- Toenail fungus secondary to diabetes
- Onychomycosis rated as scars or disfigurement
- The onychomycosis C&P exam
- Why VA denies onychomycosis claims
- Questions veterans ask about onychomycosis
- Bottom Line
- Sources and limits
VA expressly includes tinea unguium, or onychomycosis, under Diagnostic Code 7813 for dermatophytosis. It is generally evaluated under the General Rating Formula for the Skin in 38 CFR § 4.118, using either the percentage of body or exposed area affected or the duration of qualifying systemic therapy during the previous 12 months.
Nail-only disease treated only with topical medicine generally falls at 0 percent, because nails cover a small share of the body and the 10 percent level needs 5 percent of the entire body or of exposed areas, or systemic therapy. A compensable rating can still be supported when the documented area or systemic-treatment criteria are met.
This page covers the DC 7813 rating criteria, how the body-area test works for nails, oral antifungals and the systemic-therapy route, diagnosis, how to prove toenail fungus is service connected, the diabetes link, the C&P exam, and why VA denies these claims.
TL;DR
- Onychomycosis is listed under DC 7813 as tinea unguium.
- DC 7813 generally uses the 0, 10, 30, and 60-percent General Rating Formula for the Skin.
- The formula has two routes: affected body/exposed area or qualifying systemic therapy in the last 12 months.
- Topical therapy applied through the skin is treated differently from therapy administered by another route.
- Oral antifungal prescriptions, dates, and duration should be documented rather than summarized from memory.
- Nail changes have several nonfungal causes, so testing and a clinician's diagnosis can be important.
- Direct service connection rests on onset in service and a medical link; diabetes may support a secondary theory only with a case-specific causation or aggravation opinion.
- Painful scars, disfigurement, or another rating route applies only when the facts and predominant disability satisfy that code.
- Across 1,159 decided Board rulings on onychomycosis from 2021 to 2026, 20.8% were granted, 36.6% denied and 42.6% remanded. The Board section below breaks those rulings down.
Onychomycosis VA rating criteria (DC 7813)
The General Rating Formula for the Skin provides these levels.
60 percent
Characteristic lesions involving more than 40 percent of the entire body or exposed areas, or constant or near-constant systemic therapy during the past 12 months.
30 percent
Characteristic lesions involving 20 to 40 percent of the entire body or exposed areas, or systemic therapy for six weeks or more but not constantly during the past 12 months.
10 percent
Characteristic lesions involving at least 5 but less than 20 percent of the entire body or exposed areas, or intermittent systemic therapy for less than six weeks during the past 12 months.
0 percent
Characteristic lesions involving less than 5 percent of the entire body and exposed areas, with no more than topical therapy during the past 12 months.
The regulation lists the two 0 percent area measures with "or," but 5 percent on either measure already meets the 10 percent level. The regulation defines systemic therapy as treatment administered through a route other than the skin and topical therapy as treatment administered through the skin. The formula lists examples of systemic treatment but is not limited to those examples. For an oral antifungal, the record should identify the drug, route, dates, and total duration, while the rating decision should explain how that treatment fits the current formula.
How VA measures nail fungus: body area and exposed area
The body-area route can be difficult for nail-only disease because nails occupy a small percentage of the entire body. The examination should still identify every affected nail, whether fingers or toes are involved, whether surrounding skin is affected, and whether a related fungal skin condition such as tinea pedis is part of the same service-connected disease process.
VA's Skin Diseases Disability Benefits Questionnaire (DBQ) asks for the exposed area as the face, neck and hands. Fingernail disease is on the hands, so it belongs in the exposed-area estimate; toenail disease counts only toward the entire-body figure.
Photographs can show appearance and progression, but the percentage determination should come from a competent examination. A veteran should not estimate a body-surface percentage without medical support.
Oral antifungals and the systemic-therapy route
Section 4.118(a) defines systemic therapy by route: treatment given through any route other than the skin, such as by mouth. A prescription antifungal taken by mouth meets that definition on its face, and the formula's list of systemic treatments is "not limited to" the drugs it names.
The route is not the whole argument. VA's 2018 explanation of the skin rule describes systemic therapy as medication that circulates throughout the body and suppresses the immune system as a whole, and none of the formula's named examples is an antifungal. So the classification of an antifungal course can be disputed. If a decision ignored an oral antifungal or treated it as topical, it should explain why under the § 4.118(a) definition.
Because the 30 percent level needs systemic therapy for a total of six weeks or more in the past 12 months, and the 10 percent level covers less than six weeks, the start and stop dates of each oral course matter as much as the drug name.
Diagnosing onychomycosis for a VA claim
The Centers for Disease Control and Prevention notes that fingernails and toenails can become discolored or change shape for many reasons, including previous injuries, and advises talking with a healthcare provider about testing before treating a suspected fungal infection. It says prescription antifungal medicine taken by mouth is usually the best treatment, the infection can take several months to a year to go away, and it can return after treatment. A 2025 review adds that accurate diagnosis requires mycological confirmation, because the nail changes can look like other nail disorders.
Useful compensation evidence can include the following.
- dermatology or podiatry diagnosis;
- KOH preparation, culture, pathology, or other testing when performed;
- photographs taken over time;
- the number and location of affected nails;
- concurrent fungal skin findings;
- topical and oral medication histories with exact dates; and
- records of pain, nail loss, secondary infection, or functional limits.
Testing is strong evidence, but this guide does not declare one laboratory method legally mandatory in every VA claim. The key is a medically supported diagnosis that distinguishes fungal disease from trauma, psoriasis, pigment changes, or another nail disorder.
How to prove onychomycosis is service connected
Direct service connection under § 3.303 may apply when fungal nail disease began in service. Service treatment records may describe tinea, nail changes, foot complaints, or treatment. Lay evidence can describe observable thickening, discoloration, crumbling, and recurrence, but a clinician should establish the current diagnosis.
Military life is a documented setting for fungal foot and nail infections. A review of close-quarter living found onychomycosis common in settings that include military quarters and named occlusive footwear and global wars among the reasons it became more common. A small study of Danish soldiers found fungal foot and nail infections about twice as common after a six-month deployment as before it.
Communal showers, prolonged boot wear, humid environments, and field conditions may be relevant to the history. They are not automatic proof of nexus. The opinion should explain why the veteran's current disease is connected to the in-service onset or exposure rather than a later infection or another cause.
Toenail fungus secondary to diabetes
The CDC notes that people with diabetes are at increased risk for returning nail infections. A 2025 review lists age, peripheral vascular disease, poor blood sugar control, neuropathy, foot hygiene and nail trauma among the reasons onychomycosis is more common in people with diabetes. A claim under § 3.310 still needs an individualized medical opinion showing that service-connected diabetes caused or aggravated this veteran's onychomycosis. The same kind of opinion is needed for a theory based on service-connected peripheral vascular disease.
Risk is not the same as causation. The opinion should address timing, circulation, immune status, recurrence, treatment response, and other risks. For aggravation, it should say whether the onychomycosis is aggravated by the service-connected diabetes, meaning it would be less severe but for the diabetes, and identify the baseline and the worsening attributable to the service-connected condition where feasible.
Onychomycosis rated as scars or disfigurement
DC 7813 allows evaluation as disfigurement of the head, face, or neck or as scars when that is the predominant disability. Those routes are uncommon for ordinary toenail fungus and should not be added automatically. The medical facts must show the qualifying location and impairment.
Separate ratings for overlapping manifestations are prohibited by § 4.14. Section 4.118(b) adds that two skin conditions are combined only when they involve separate areas of skin; when they involve the same area, only the highest evaluation is used. When several fungal diagnoses affect the same area, VA should avoid counting the same lesions or treatment twice.
The onychomycosis C&P exam
The record should answer these questions.
- Is the nail condition medically diagnosed as onychomycosis?
- Which nails and surrounding skin areas are affected?
- What percentage of the whole body and exposed areas is involved?
- What topical and systemic treatments were used in the previous 12 months?
- What were the route and total duration of each treatment?
- When did observable disease begin, and has it recurred continuously?
- Does a service-connected condition cause or aggravate it?
- Is another diagnosis a better explanation for the nail changes?
Why VA denies onychomycosis claims
Onychomycosis claims do a little worse at the Board than the average claim. Across 1,159 decided Board rulings on onychomycosis from 2021 to 2026, 20.8% were granted, 36.6% denied and 42.6% remanded. That grant rate is 3.9 points below the Board-wide 24.7 percent.
When the Board denies onychomycosis service connection, it is usually over the link to service, followed by no in-service event or onset, and less often by no current diagnosis. The patterns repeat.
No medical link. Communal showers, boots or field conditions are offered as the cause, but no opinion explains why this veteran's current infection traces to service rather than a later infection.
Nothing in service. Service records are silent about nail or foot fungus, and the first treatment comes years later with no account of the gap.
No confirmed diagnosis. Discoloration alone is treated as proof of fungal disease, with no testing or clinician diagnosis to rule out trauma, psoriasis, or another nail disorder.
A secondary opinion that skips aggravation. For a diabetes theory, an opinion that says only "not caused by" without addressing whether diabetes made the nail disease worse is inadequate (El-Amin v. Shinseki, 26 Vet. App. 136 (2013)). Diabetes alone, like communal living alone, does not establish nexus without a case-specific opinion.
Rating errors repeat too.
- Using DC 7820 when DC 7813 expressly lists tinea unguium or onychomycosis.
- Assuming every oral prescription guarantees a particular percentage without documenting duration and the current formula.
- Calling topical medication systemic solely because it has effects beyond the application site.
- Estimating body-surface percentages without an examination.
- Counting the same lesions and therapy under multiple skin diagnoses.
When the Board sends an onychomycosis claim back instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get and claims that never had a VA exam. The Board section below shows the denial and remand reasons, results by what the appeal asked for, and how claims argued as direct, secondary and presumptive have fared.
Questions veterans ask about onychomycosis
Is toenail fungus a VA disability?
Yes, when it is service connected. VA rates onychomycosis, which the schedule lists as tinea unguium, under DC 7813 with the General Rating Formula for the Skin, from 0 to 60 percent. Nail-only disease treated with topical medicine is generally rated 0 percent, which still means it is service connected.
What is the highest VA rating for onychomycosis?
60 percent, for lesions on more than 40 percent of the entire body or exposed areas, or constant or near-constant systemic therapy over the past 12 months. Because nails cover a small share of the body, a rating above 0 percent for nail-only disease usually depends on the systemic-therapy route unless the infection also involves surrounding skin.
Does an oral antifungal count as systemic therapy for a VA skin rating?
By route it qualifies, because 38 CFR § 4.118(a) defines systemic therapy as treatment given by any route other than the skin, such as by mouth. VA's 2018 explanation of the rule also describes systemic therapy as medication that suppresses the immune system, so the classification can still be disputed. Make sure the record shows the drug, that it was taken by mouth, and its start and stop dates within the past 12 months.
Can toenail fungus be secondary to diabetes?
Yes, if a medical opinion explains how your service-connected diabetes caused or worsened it. The CDC notes that people with diabetes are at increased risk for returning nail infections, but a general risk is not proof for your case. The opinion has to address your own history and other possible causes.
Can VA rate toenail fungus and athlete's foot separately?
Both are dermatophytosis under DC 7813. Under 38 CFR § 4.118(b), two skin conditions are rated separately only when they involve separate areas of skin; when they involve the same area, VA uses only the highest evaluation.
Bottom Line
An onychomycosis claim should document the fungal diagnosis, every affected nail and skin area, the exact route and duration of treatment during the prior 12 months, and the service-connection timeline. The rating usually turns on small-area versus systemic-treatment evidence, not on how unpleasant the nail appearance is by itself.
Sources and limits
Legal and medical sources: 38 CFR § 4.118, § 3.303, § 3.310, § 4.14, and CDC fungal nail treatment guidance, checked October 6, 2026 against the eCFR text current on October 1, 2026 and the CDC page dated February 9, 2026. The route discussion also draws on VA's 2018 skin rule (83 FR 32592, effective August 13, 2018), the exposed-area definition on VA's Skin Diseases DBQ (updated July 15, 2024), and El-Amin v. Shinseki, 26 Vet. App. 136 (2013).
Medical studies, each read as a PubMed abstract: Gupta et al., "Onychomycosis in special populations," Future Microbiology (2025); Gupta et al., "Onychomycosis in Diabetics," Life (2025); Gazes and Zeichner, "Onychomycosis in close quarter living," Mycoses (2013); and Brocks et al., "Tinea pedis and onychomycosis in Danish soldiers before and after service in ex-Yugoslavia," Mycoses (1999), a study of 73 soldiers.
Board figures come from Claim Raven's read of 510,968 Board decisions from 2021 to 2026, which contain 1,376,193 rulings. Of 1,285 Board rulings on onychomycosis, 1,159 were decided; dismissed, withdrawn and moot rulings are excluded from the shares, and the Board section below is computed from the same data. These are Board patterns, not predictions of an individual outcome.
